Erasca Rejected $20 Twice—Now $16.50 Is the Wall Between a Bounce and the 200-Day

Erasca (NASDAQ: ERAS) closed September 1 at $16.76, down 6.3% and at the low end of its range, sliding under its 50-day average after a month of fading from the ~$20 July peak. The low-$16s are the last line of defense for a stock that has roughly quadrupled since the start of the year. Hold them and the post-crash recovery stays alive; lose them and the chart offers no real floor until the 200-day at $12.64.

Let's put the clock on this. The stock opened the September session near $17.58, tagged $17.95, and then got sold straight down to a $16.68 low before closing at $16.76 on roughly 6.7 million shares. That is not an erratic penny-stock wobble—a single 6% red day against an average true range just over a dollar is close to an entire average range handed back in one session, and it came at the end of a 20-day stretch that is already down about 9%. The medium-term trend just flipped: ERAS closed below its 50-day moving average at $18.22, with RSI at 41 and MACD still rolling over.

The context is what makes the level matter. This is a clinical-stage oncology name whose lead drug, ERAS-0015, is an oral pan-RAS molecular glue, and the chart has been a war for most of 2026. The stock opened the year near $3.60, rode RAS hype and early clinical signals up to a ~$24 peak in April, and then collapsed 46% in a single morning on April 28 even though the phase 1 readout was strong enough that an Evercore analyst called it a "home run profile." Two things did the damage: a patient death tied to drug-related lung inflammation, and a patent-plus-trade-secret lawsuit from rival Revolution Medicines. That is a lot of inventory that has been underwater ever since.

What happened next is the part worth reading twice. The stock did not stay down. It clawed back from roughly $11 in late May toward resistance near $20 in mid-July, when updated data showed a 57% response rate in second-line-plus pancreatic cancer, and it had another catalyst in hand on August 24 when the FDA granted fast-track designation for ERAS-0015 in metastatic pancreatic cancer. That was the second chance to relaunch. On the fast-track day the stock gapped up to about $18.41 and promptly faded to close at $17.60. It has gone essentially nowhere good since.

That is the repeating shape of this chart: every attempt to reconquer the $18.70–$20 supply zone from the July peak has been sold. The market has now had two headline catalysts to justify a breakout, and both died at the same wall. That failure to hold a fresh catalyst is why today's fade under the 50-day deserves attention rather than a shrug.

Everything now runs through the low-$16s. Today's low was $16.68, and the August low near $16.88 is stacked almost on top of it, so roughly $16.50–$17 is a zone with actual memory—repeated reaction, not a round number pulled off the tape. The decision works like this:

• Hold $16.50–$17 and the uptrend from the May low near $11 is still intact, leaving a bounce back into the $18.70 area that served as the July ceiling, then the $20 resistance if that gives way.
• Close below $16.50 and there is a thin air pocket down to the 200-day at $12.64. That is a 24% slide from here, and it would hand back nearly all of the spring-and-summer recovery and trap the buyers who pushed price through the $17–$18 zone in August.

Scenario	Trigger	Path	Invalidation	Horizon
Rebound	Reclaim and hold $17.60–$18 (the 50-day is $18.22)	Retest $18.70 July supply, then $20	Close back under ~$16.50	Sessions to weeks
Breakdown	Close below ~$16.50	Air pocket toward $15, then the 200-day at $12.64	Reclaim above $17.60	Sessions to weeks

Here is what most casual readers are missing in the flush: on a day the stock dropped 6%, the block-order tape still showed about $17.8 million of block inflow against $10.9 million of block outflow, while the retail-sized flow was roughly net neutral. Bigger tickets were absorbing this dip into support even as the retail order flow stayed flat. That does not prove a bottom, and it does not identify the buyer—but it is a divergence worth knowing, because a support test that is being bought by institutional-size blocks looks different from one that is breaking on genuine distribution.

Two caveats keep this honest. First, a 57% pancreatic response rate in a small phase 1 cohort is unconfirmed data in a tiny patient pool, and the patient-fatality and litigation overhang from April has not been resolved. Second, fast-track setting is not approval—it is a priority lane, and the next hard clinical catalyst (monotherapy expansion and combination data) is not expected until the first half of 2027. That long gap is exactly why the market is trading the chart now instead of waiting for the data.

So the verdict is a binary the chart can resolve in the coming sessions. Hold the low-$16s and rebuild above $17.60, and the failed-fast-track scare reads as one more shakeout inside a still-rising 2026 story. Lose $16.50 on a closing basis and the recovery structure is broken, with no meaningful support until the 200-day at $12.64. ERAS has rejected its $20 ceiling twice. The question now is whether the $16.50 floor holds long enough to make bears the ones who get trapped.

Data as of the September 1, 2026 close; premarket September 2 session may have moved the tape. ATR and moving averages are daily technical readings; ERAS is a clinical-stage biotech with no approved products and zero revenue.